Comparison of mortality risk, swollen joints, tender joints and functional disability between cohort 1 and cohort 2 over time
| N (number of events) | Age-adjusted and gender-adjusted, HR/SHR (95% CI) | Adjusted for baseline variables*, HR/SHR (95% CI) | Adjusted for baseline variables* and time-varying smoking, HR/SHR (95% CI) | Adjusted for baseline variables* and time-varying treatment/smoking, HR/SHR (95% CI) | |
| Mortality risk† | |||||
| Patients with IP | 1653 (291) | 0.76 (0.60 to 0.96) | 0.72 (0.56 to 0.95) | 0.73 (0.56 to 0.95) | 0.77 (0.58 to 1.02) |
| Patients with RA | 961 (178) | 0.87 (0.64 to 1.19) | 0.83 (0.59 to 1.18) | 0.85 (0.60 to 1.20) | 0.95 (0.65 to 1.38) |
| Cancer mortality risk† | |||||
| Patients with IP | 1653 (91) | 0.97 (0.64 to 1.49) | 1.06 (0.66 to 1.73) | 1.06 (0.65 to 1.72) | 1.04 (0.60 to 1.77) |
| Patients with RA | 961 (55) | 1.03 (0.60 to 1.79) | 1.25 (0.67 to 2.32) | 1.26 (0.67 to 2.35) | 1.26 (0.60 to 2.62) |
| CVD mortality risk† | |||||
| Patients with IP | 1653 (106) | 0.61 (0.40 to 0.93) | 0.58 (0.37 to 0.93) | 0.53 (0.33 to 0.84) | 0.61 (0.37 to 0.99) |
| Patients with RA | 961 (68) | 0.69 (0.41 to 1.18) | 0.61 (0.34 to 1.12) | 0.61 (0.34 to 1.12) | 0.79 (0.41 to 1.52) |
| Respiratory disease mortality risk† | |||||
| Patients with IP | 1653 (43) | 1.26 (0.67 to 2.35) | 1.33 (0.67 to 2.66) | 1.11 (0.54 to 2.28) | 1.01 (0.45 to 2.25) |
| Patients with RA | 961 (25) | 1.63 (0.75 to 3.53) | 1.50 (0.61 to 3.69) | 1.54 (0.64 to 3.72) | 1.57 (0.62 to 4.00) |